Stock Analysis
Amid fluctuating global market conditions, the Hong Kong stock market has shown resilience, with particular interest in growth companies boasting high insider ownership. Such firms often signal strong confidence from those closest to the company's operations and strategic direction, making them noteworthy in the current economic landscape.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
| Name | Insider Ownership | Earnings Growth |
| iDreamSky Technology Holdings (SEHK:1119) | 20.2% | 104.1% |
| Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
| Tian Tu Capital (SEHK:1973) | 34% | 70.5% |
| Adicon Holdings (SEHK:9860) | 22.4% | 28.3% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 100.1% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 73.4% |
| DPC Dash (SEHK:1405) | 38.2% | 90.5% |
| Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.7% | 79.3% |
| Ocumension Therapeutics (SEHK:1477) | 23.3% | 93.7% |
| Beijing Airdoc Technology (SEHK:2251) | 28.7% | 83.9% |
Let's uncover some gems from our specialized screener.
Xiamen Yan Palace Bird's Nest Industry (SEHK:1497)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Xiamen Yan Palace Bird's Nest Industry Co., Ltd. operates in the research, development, production, and marketing of edible bird’s nest products within the People’s Republic of China, with a market capitalization of HK$6.60 billion.
Operations: The company generates revenue through several channels: CN¥16.75 million from sales to online distributors, CN¥509.04 million from sales to offline distributors, CN¥824.40 million from direct sales to online customers, CN¥351.17 million from direct sales to offline customers, and CN¥262.89 million from direct sales to e-commerce platforms.
Insider Ownership: 26.7%
Return On Equity Forecast: 27% (2026 estimate)
Xiamen Yan Palace Bird's Nest Industry, a growth-oriented company with high insider ownership, is navigating a complex market landscape. Despite a challenging first half of 2024, it managed to grow its revenue by 10% to 15% year-over-year, reaching RMB 1.045 billion to RMB 1.09 billion. However, its net profit is expected to decrease significantly by approximately 40% to 50%. The company's earnings are forecasted to grow at an annual rate of 14.84%, outpacing the Hong Kong market average of 11.3%. Additionally, its Return on Equity is projected at a robust level in three years' time (27.3%).
- Click to explore a detailed breakdown of our findings in Xiamen Yan Palace Bird's Nest Industry's earnings growth report.
- The analysis detailed in our Xiamen Yan Palace Bird's Nest Industry valuation report hints at an inflated share price compared to its estimated value.
Beauty Farm Medical and Health Industry (SEHK:2373)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Beauty Farm Medical and Health Industry Inc. operates in the healthcare sector and has a market capitalization of approximately HK$3.97 billion.
Operations: Beauty Farm Medical and Health Industry generates revenue from several segments, including Aesthetic Medical Services (CN¥850.36 million), Subhealth Medical Services (CN¥101.04 million), and Beauty and Wellness Services through both direct stores (CN¥1.08 billion) and franchisees (CN¥113.81 million).
Insider Ownership: 33.9%
Return On Equity Forecast: 23% (2026 estimate)
Beauty Farm Medical and Health Industry Inc., despite trading 47.2% below its fair value, shows promising growth prospects with substantial earnings growth expected at 20.1% per year, outpacing the Hong Kong market's 11.3%. The company's revenue is also set to grow faster than the market at 18.3% annually. Additionally, it recently increased its dividend to HK$0.47 per share, reflecting confidence in sustained profitability which grew by 109.2% over the past year; a testament to robust internal management and operational efficiency.
- Unlock comprehensive insights into our analysis of Beauty Farm Medical and Health Industry stock in this growth report.
- Our expertly prepared valuation report Beauty Farm Medical and Health Industry implies its share price may be too high.
Adicon Holdings (SEHK:9860)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Adicon Holdings Limited, operating medical laboratories in the People’s Republic of China, has a market capitalization of approximately HK$6.63 billion.
Operations: The company generates revenue primarily from its healthcare facilities and services segment, amounting to CN¥3.30 billion.
Insider Ownership: 22.4%
Return On Equity Forecast: 20% (2026 estimate)
Adicon Holdings, with high insider ownership, is poised for significant growth. Analysts predict a 61.3% potential increase in stock price as the company's earnings are expected to grow by 28.33% annually over the next three years, outpacing the Hong Kong market average of 11.3%. Additionally, Adicon has initiated a share repurchase program which could enhance shareholder value by potentially increasing net asset value and earnings per share. However, its current profit margins at 7.1% have declined from previous levels of 14%.
- Delve into the full analysis future growth report here for a deeper understanding of Adicon Holdings.
- According our valuation report, there's an indication that Adicon Holdings' share price might be on the expensive side.
Seize The Opportunity
- Gain an insight into the universe of 54 Fast Growing SEHK Companies With High Insider Ownership by clicking here.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.
Contemplating Other Strategies?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:1497
Xiamen Yan Palace Bird's Nest Industry
Engages in the research, development, production, and marketing of edible bird’s nest (EBN) products in the People’s Republic of China.
Flawless balance sheet with reasonable growth potential.
